Yutaka Inaba

Dr. Yutaka Inaba

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Nobuo KanazawaNobuo Kanazawa
Nobuo Kanazawa
HHHiroaki Hemmi
Hiroaki Hemmi
NKNoriko Kinjo
Noriko Kinjo
HOHidenori Ohnishi
Hidenori Ohnishi
JHJun Hamazaki
Jun Hamazaki
TKTsuneyasu Kaisho
Tsuneyasu Kaisho
Impaired proteasome activity due to genetic variants of certain subunits might lead to proteasome-associated autoinflammatory syndromes (PRAAS). Here we report a de novo heterozygous missense variant of the PSMB9 proteasome subunit gene in two unrelated Japanese infants resulting in amino acid substitution of the glycine (G) by aspartic acid (D) at position 156 of the encoded protein β1i. In addition to PRAAS-like manifestations, these individuals suffer from pulmonary hypertension and immunodeficiency, which are distinct from typical PRAAS symptoms. The missense variant results in impaired immunoproteasome maturation and activity, yet ubiquitin accumulation is hardly detectable in the patients. A mouse model of the heterozygous human genetic variant (Psmb9G156D/+) recapitulates the proteasome defects and the immunodeficiency phenotype of patients. Structurally, PSMB9 G156D interferes with the β-ring-βring interaction of the wild type protein that is necessary for 20S proteasome formation. We propose the term, proteasome-associated autoinflammatory syndrome with immunodeficiency (PRAAS-ID), to indicate a separate category of autoinflammatory diseases, similar to, but distinct from PRAAS, that describes the patients in this study.

24 February 2022 in Children
Verified
Journal Article
Open access
PDF file
YIYutaka Inaba
Yutaka Inaba
Nobuo KanazawaNobuo Kanazawa
Nobuo Kanazawa
KMKyoko Muraoka
Kyoko Muraoka
AYAzusa Yariyama
Azusa Yariyama
AKAmi Kawaguchi
Ami Kawaguchi
MJMasatoshi Jinnin
Masatoshi Jinnin
The patient was a 26-year-old male. He had red and scaling skin of the entire body since birth, as well as an elevated level of serum IgE. Genetic testing revealed a mutation in the SPINK5 gene, which had confirmed the diagnosis with Netherton syndrome. He has had significant pruritis since birth, and subsequently had symptoms of sleeping disorders and concentration difficulty throughout the day. Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash. Dupilumab has been administered for one year without any adverse events or recurrence of symptoms. Although studies have previously described cases who used dupilumab for Netherton syndrome, reported effects have been limited or transient. Additional studies are needed to confirm the effect of dupilumab for Netherton syndrome, which currently lack any effective treatment strategies.

1 August 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SRSabine Ring
Sabine Ring
YIYutaka Inaba
Yutaka Inaba
MDMeihong Da
Meihong Da
TBTobias Bopp
Tobias Bopp
Stephan GrabbeStephan Grabbe
Stephan Grabbe
KMKarsten Mahnke
Karsten Mahnke

1 October 2018 in Human Pathology
Verified
Journal Article
Closed access
MFMasakazu Fujimoto
Masakazu Fujimoto
YTYuki Togashi
Yuki Togashi
IMIbu Matsuzaki
Ibu Matsuzaki
SBSatoko Baba
Satoko Baba
KTKengo Takeuchi
Kengo Takeuchi
SMShin-Ichi Murata
Shin-Ichi Murata

4 August 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
YMYasunori Matsuki
Yasunori Matsuki
RKRana Kawai
Rana Kawai
TSTakayuki Suyama
Takayuki Suyama
KKKazumoto Katagiri
Kazumoto Katagiri
Nobuo KanazawaNobuo Kanazawa
Nobuo Kanazawa
YIYutaka Inaba
Yutaka Inaba

6 July 2022 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
KGKeisuke Goto
Keisuke Goto
KOKohei Ogawa
Kohei Ogawa
THTsunekazu Hishima
Tsunekazu Hishima
NONaoki Oishi
Naoki Oishi
OTOzumi Tomita
Ozumi Tomita
KHKeiichiro Honma
Keiichiro Honma
Seborrheic keratosis is a common benign neoplasm composed of basaloid keratinocytes. However, little is known about the malignant transformation of the tumor. Eleven cases of seborrheic keratosis with malignant transformation were analyzed. The 11 patients included 5 male patients and 6 female patients with a median age of 75 years at diagnosis (68–90 years). The tumors arose at various sites from the scalp (n = 3) to the lower leg (n = 2). The median tumor size was 12 (10–32) and 40 (20–75) mm in 7 noninvasive and 4 invasive cases, respectively. One patient exhibited in-transit skin metastasis. Histopathology of the malignant components resembled porocarcinoma or inverted follicular keratosis. Bowenoid and pagetoid spreading was frequently observed. The malignant components expressed cytokeratin 5/6 (100%) and GATA3 (73%), but not cytokeratin 7 (0%), cytokeratin 19 (9%), BerEP4 (0%), c-kit (0%), and NUT (0%). No significant immunoreactivity of YAP1 was observed in any of the cases. Mutant-type immunostaining of p53 and PTEN was observed in 91% and 82% of the cases, respectively. An increase in p16 expression was seen in 6 (86%) of the 7 cases with noninvasive carcinoma, although a loss of p16 immunoexpression was seen in the invasive carcinoma component in 3 (75%) of the 4 cases. This study demonstrated that seborrheic keratosis can undergo malignant transformation, particularly in large-sized lesions in elderly patients. Malignant components mimic porocarcinoma or inverted follicular keratosis. Malignant transformation induced by TP53 and PTEN mutations and tumor invasion by CDKN2A inactivating mutations are suggested in this study.